ES2337005R - PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS. - Google Patents

PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS. Download PDF

Info

Publication number
ES2337005R
ES2337005R ES200850016A ES200850016A ES2337005R ES 2337005 R ES2337005 R ES 2337005R ES 200850016 A ES200850016 A ES 200850016A ES 200850016 A ES200850016 A ES 200850016A ES 2337005 R ES2337005 R ES 2337005R
Authority
ES
Spain
Prior art keywords
preparation
compounds
azepan
azocansustituidos
pirazolina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200850016A
Other languages
Spanish (es)
Other versions
ES2337005A2 (en
ES2337005B1 (en
Inventor
Antonio Torrens Jover
Susana Yenes Minguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384018A external-priority patent/EP1743888A1/en
Priority claimed from EP06008612A external-priority patent/EP1849776A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2337005A2 publication Critical patent/ES2337005A2/en
Publication of ES2337005R publication Critical patent/ES2337005R/en
Application granted granted Critical
Publication of ES2337005B1 publication Critical patent/ES2337005B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de pirazolina azepan o azocansustituidos, su preparación y su uso como medicamentos.Pyrazoline compounds azepan o azocansustituidos, its preparation and its use as medicines.

La presente invención se refiere a compuestos de pirazolina azepan o azocansustituidos, procedimientos para su preparación, medicamentos que comprenden estos compuestos así como su uso para la preparación de un medicamento para el tratamiento de seres humanos y animales.The present invention relates to compounds of pyrazoline azepan or azocansubstituted, procedures for its preparation, medicines comprising these compounds as well as its use for the preparation of a medicine for the treatment of human beings and animals

ES200850016A 2005-07-15 2006-07-16 COMPOUNDS OF PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS, ITS PREPARATION AND ITS USE AS MEDICINES. Expired - Fee Related ES2337005B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/705,433 2005-07-15
EP06008612 2005-07-15
EP05384018A EP1743888A1 (en) 2005-07-15 2005-07-15 Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
EP05384018 2005-07-15
US70543305P 2005-08-05 2005-08-05
EP06008612A EP1849776A1 (en) 2006-04-26 2006-04-26 Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments

Publications (3)

Publication Number Publication Date
ES2337005A2 ES2337005A2 (en) 2010-04-19
ES2337005R true ES2337005R (en) 2010-04-23
ES2337005B1 ES2337005B1 (en) 2011-01-10

Family

ID=37326377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200850016A Expired - Fee Related ES2337005B1 (en) 2005-07-15 2006-07-16 COMPOUNDS OF PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS, ITS PREPARATION AND ITS USE AS MEDICINES.

Country Status (2)

Country Link
ES (1) ES2337005B1 (en)
WO (1) WO2007131538A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (en) * 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2005037199A2 (en) * 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
HRP20080549T3 (en) * 2004-01-30 2008-11-30 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ITMI20041032A1 (en) * 2004-05-24 2004-08-24 Neuroscienze S C A R L PHARMACEUTICAL COMPOSITES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANGE, J. H.M. y col. Biososteric replacement of the pyrazole moiety of Rimonabant: synthesis, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry. 2005, Vol. 48, páginas 1823-1838, ISSN 0022-2623. Todo el documento. *

Also Published As

Publication number Publication date
ES2337005A2 (en) 2010-04-19
WO2007131538A1 (en) 2007-11-22
ES2337005B1 (en) 2011-01-10

Similar Documents

Publication Publication Date Title
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
GT200500384A (en) PHARMACEUTICAL DOSAGE METHODS ADMINISTRABLE SOLIDS BY ROUTE WITH MODIFIED RELEASE
CR9514A (en) NPY ANTAGONISTS, PREPARATION AND USES
ECSP045353A (en) DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND APPLICATION AS MEDICATIONS
CL2007003352A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROMONOCYCLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CIRCULATORY DISEASES, METABOLIC DISEASES AND / OR DISEASES OF THE CEN NERVOUS SYSTEM
BRPI0820868A2 (en) thiophene compound formula (i), pharmaceutical composition containing it and use thereof for the prevention or treatment of diseases or disorders associated with an activated immune system
EA201290078A1 (en) HETEROCYCLIC COMPOUNDS TO INHIBIT PASK
GT201200313A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
GT200900095A (en) REPLACED DIHYDROPIRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HERMATOLOGICAL DISEASES.
HN2005000255A (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
BRPI1009252A2 (en) compound, prodrug, pharmaceutical composition, methods for preventing or treating central nervous system disease, and alzheimer's disease, and use of the compound or a prodrug thereof
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
CR10336A (en) ORGANIC COMPOUNDS AND THEIR USES
GT200500378A (en) MACROLIDOS
BRPI0507790A (en) substituted pyrazoline compound, process for its manufacture, medicines and their uses
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
CL2008001820A1 (en) Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases.
PT1781298E (en) PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINS FOR THE TREATMENT OF RESPIRATORY DISEASES
CL2008000596A1 (en) DOSAGE FORM INCLUDING 1- (6 - [(3-CYCLLOBUTIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-IL) OXI] -3-PIRIDINIL) -2-PIRROLIDINONA, A STABILIZER , A EXCIPIENT; PREPARATION PROCEDURE; AND ITS USE TO TREAT NEUROLOGICAL DISEASES.
PA8806501A1 (en) TRIAZOLOTRIAZINAS AND TRIAZOLOPIRAZINAS AND ITS USE
GT200600109A (en) PYRIMIDINCARBOXILIC ACID DERIVATIVES AND ITS USE
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
CL2007000485A1 (en) ALISQUERENO SALT; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SALT; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES THAT CAN BE MODULATED BY THE INHIBITION OF THE RHENINE.
HN2003000104A (en) CYCLOPENTENE DERIVATIVES
DOP2006000024A (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
EC2A Search report published

Ref document number: 20100419

FG2A Definitive protection

Ref document number: 2337005

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20101227

FD2A Announcement of lapse in spain

Effective date: 20190610